Low Level LASER Therapy With and Without Proprioceptive Stimulation Among Discogenic Lumbar Radiculopathy Patients
Launched by RIPHAH INTERNATIONAL UNIVERSITY · Jul 12, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the effects of low level laser therapy on patients with a specific type of back pain called discogenic lumbar radiculopathy, which means pain that radiates from the lower back into the legs due to a bulging disc. The researchers want to see if adding proprioceptive stimulation, which helps your body sense its position and movement, will improve outcomes like pain relief, feeling in the legs, and walking ability better than just the laser therapy alone.
To be eligible for this study, participants need to be between 45 and 70 years old, have been experiencing severe lower back pain with leg pain for less than four weeks, and should have a specific type of disc problem confirmed by an MRI. During the trial, participants will be randomly assigned to one of two groups: one will receive both laser therapy and proprioceptive stimulation, while the other will receive only the laser therapy. Both groups will also be given heating packs for comfort. This trial is currently recruiting, so if you or someone you know meets these criteria and is interested, it could be a good opportunity to explore new treatment options for back pain.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age: 45-70years(27)
- • Both male and female patients
- • Patients with acute Low Back Pain and unilateral Discogenic Lumbar Radiculopathy with disc bulge confirmed on MRI
- • Pain intensity score is 4 or more on the numeric pain rating scale (NPRS)
- • Radiating leg pain symptoms for less than 4 weeks
- • Numbness and paresthesia in the affected area
- • Patients with moderate to severe score (21%-60%) in ODI
- Exclusion Criteria:
- • Non willing patients
- • Patients with severely cognitive disorders
- • History of low back pain for more than 4 weeks
- • History of any systemic disease such as Stroke, Multiple Sclerosis, Myopathies, Heart Failure etc
- • Botulinum toxin injections to any lower extremity muscle in the last 3 months
- • Malignancy
About Riphah International University
Riphah International University is a leading educational institution based in Pakistan, dedicated to advancing healthcare and medical research through innovative clinical trials. With a commitment to excellence in research and education, Riphah emphasizes ethical standards and scientific integrity in its clinical studies. The university collaborates with various stakeholders, including healthcare professionals and industry partners, to enhance patient outcomes and contribute to the global body of medical knowledge. Through its robust research programs, Riphah International University aims to foster a culture of inquiry and improve healthcare delivery both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bahawalpur, Punjab, Pakistan
Bahawalpur, Punjab, Pakistan
Patients applied
Trial Officials
Hira Jabeen
Principal Investigator
Riphah International University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported